Arch Therapeutics Inc. logo

Arch Therapeutics Inc. (ARTH)

Delisted
OTCQB OTCQB
Want to track ARTH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ARTH is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTCQB (USD).

Arch Therapeutics Inc. Profile

- Industry
- Sector
Dr. Terrence W. Norchi M.D. CEO
OTCQB Exchange
US03939W1099 ISIN
United States Country
8 Employees
- Last Dividend
18 Jan 2023 Last Split
- IPO Date

Overview

Arch Therapeutics, Inc., alongside its subsidiaries, positions itself within the United States as a pioneering entity in the biotechnology sector. The essence of its operations is encapsulated in the development and commercialization of innovative solutions derived from its proprietary AC5 self-assembling technology platform. This platform is heralded for its efficacy in arresting bleeding, managing leaks, and navigating the intricacies of wound care across a spectrum encompassing surgery, trauma, interventional procedures, and conditions borne out of disease. Having planted its roots in 2006, the company commands a strategic base in Framingham, Massachusetts, reflecting a blend of seasoned experience and locality which nurtures innovation.

Products and Services

  • AC5 Advanced Wound System: This offering stands at the forefront of Arch Therapeutics' product suite, specifically tailored for skin application scenarios. It addresses the management of complex chronic wounds and acute surgical wounds, marking a significant stride in the realm of wound care and management. The AC5 Advanced Wound System epitomizes the company's commitment to bridging the gap between innovative technology and real-world clinical needs.
  • AC5 Topical Hemostat: Operating in tandem with the advanced wound system, the AC5 Topical Hemostat carves its niche in the quick cessation of bleeding. Tailored for immediate application, this product champions the cause of efficiency and effectiveness in bleeding control, marking a pivotal milestone in surgical and trauma care scenarios.
  • AC5-G for Gastrointestinal Endoscopic Procedures: Progressing beyond the skin, Arch Therapeutics ventures into the gastrointestinal domain with AC5-G. This product iteration is specifically designed for endoscopic procedures within the GI tract, indicating a versatile extension of the AC5 technology platform in addressing internal bleeding challenges encountered during endoscopic interventions.
  • AC5-V and AC5 Surgical Hemostat: Further elaborating on the theme of versatility, the AC5-V along with the AC5 Surgical Hemostat underscore the company's foray into hemostasis within the body’s internal cavities. These products are earmarked for their pivotal role in surgical procedures, offering innovative solutions for internal hemostasis, thereby highlighting the adaptability and potential of the AC5 technology platform in catering to a broad spectrum of medical applications.

Contact Information

Address: 235 Walnut Street
Phone: 617 431 2313